Peringatan Keamanan

Oral, mouse: LD50 = 1220 mg/kg; Oral, rabbit: LD50 = 1370 mg/kg; Oral, rat: LD50 = 940 mg/kg. No reported case of overdosage in humans.

Clofibrate

DB00636

small molecule approved investigational

Deskripsi

A fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986)

Struktur Molekul 2D

Berat 242.699
Wujud liquid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Half-life in normal volunteers averages 18 to 22 hours (range 14 to 35 hours) but can vary by up to 7 hours in the same subject at different times.
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Completely but slowly absorbed from the intestine. Between 95% and 99% of an oral dose of clofibrate is excreted in the urine as free and conjugated clofibric acid; thus, the absorption of clofibrate is virtually complete.

Metabolisme

Hepatic and gastrointestinal: rapid de-esterification occurs in the gastrointestinal tract and/or on first-pass metabolism to produce the active form, clofibric acid (chlorophenoxy isobutyric acid CPIB).

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Take with food. Food decreases the risk of GI side effects.

Interaksi Obat

490 Data
Aripiprazole The metabolism of Aripiprazole can be increased when combined with Clofibrate.
Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be increased when combined with Clofibrate.
Ifosfamide The metabolism of Ifosfamide can be increased when combined with Clofibrate.
Perampanel The metabolism of Perampanel can be increased when combined with Clofibrate.
Warfarin The metabolism of Warfarin can be increased when combined with Clofibrate.
Acenocoumarol The metabolism of Acenocoumarol can be increased when combined with Clofibrate.
(R)-warfarin The metabolism of (R)-warfarin can be increased when combined with Clofibrate.
R,S-Warfarin alcohol The metabolism of R,S-Warfarin alcohol can be increased when combined with Clofibrate.
S,R-Warfarin alcohol The metabolism of S,R-Warfarin alcohol can be increased when combined with Clofibrate.
(S)-Warfarin The metabolism of (S)-Warfarin can be increased when combined with Clofibrate.
Fenofibrate The risk or severity of adverse effects can be increased when Clofibrate is combined with Fenofibrate.
Gemfibrozil The risk or severity of adverse effects can be increased when Clofibrate is combined with Gemfibrozil.
Bezafibrate The risk or severity of adverse effects can be increased when Clofibrate is combined with Bezafibrate.
Etofibrate The risk or severity of adverse effects can be increased when Clofibrate is combined with Etofibrate.
Ciprofibrate The risk or severity of adverse effects can be increased when Clofibrate is combined with Ciprofibrate.
Simfibrate The risk or severity of adverse effects can be increased when Clofibrate is combined with Simfibrate.
Ronifibrate The risk or severity of adverse effects can be increased when Clofibrate is combined with Ronifibrate.
Aluminium clofibrate The risk or severity of adverse effects can be increased when Clofibrate is combined with Aluminium clofibrate.
Clofibride The risk or severity of adverse effects can be increased when Clofibrate is combined with Clofibride.
Fenofibric acid The risk or severity of adverse effects can be increased when Clofibrate is combined with Fenofibric acid.
Ezetimibe The serum concentration of Ezetimibe can be increased when it is combined with Clofibrate.
Glycochenodeoxycholic Acid The therapeutic efficacy of Glycochenodeoxycholic Acid can be decreased when used in combination with Clofibrate.
Cholic Acid The therapeutic efficacy of Cholic Acid can be decreased when used in combination with Clofibrate.
Glycocholic acid The therapeutic efficacy of Glycocholic acid can be decreased when used in combination with Clofibrate.
Deoxycholic acid The therapeutic efficacy of Deoxycholic acid can be decreased when used in combination with Clofibrate.
Taurocholic acid The therapeutic efficacy of Taurocholic acid can be decreased when used in combination with Clofibrate.
Obeticholic acid The therapeutic efficacy of Obeticholic acid can be decreased when used in combination with Clofibrate.
Chenodeoxycholic acid The therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Clofibrate.
Taurochenodeoxycholic acid The therapeutic efficacy of Taurochenodeoxycholic acid can be decreased when used in combination with Clofibrate.
Tauroursodeoxycholic acid The therapeutic efficacy of Tauroursodeoxycholic acid can be decreased when used in combination with Clofibrate.
Bamet-UD2 The therapeutic efficacy of Bamet-UD2 can be decreased when used in combination with Clofibrate.
Dehydrocholic acid The therapeutic efficacy of Dehydrocholic acid can be decreased when used in combination with Clofibrate.
Hyodeoxycholic Acid The therapeutic efficacy of Hyodeoxycholic Acid can be decreased when used in combination with Clofibrate.
Ursodeoxycholic acid The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Clofibrate.
Cyclosporine The risk or severity of renal failure can be increased when Cyclosporine is combined with Clofibrate.
Glimepiride The risk or severity of hypoglycemia can be increased when Clofibrate is combined with Glimepiride.
Acetohexamide The risk or severity of hypoglycemia can be increased when Clofibrate is combined with Acetohexamide.
Chlorpropamide The risk or severity of hypoglycemia can be increased when Clofibrate is combined with Chlorpropamide.
Tolazamide The risk or severity of hypoglycemia can be increased when Clofibrate is combined with Tolazamide.
Glyburide The risk or severity of hypoglycemia can be increased when Clofibrate is combined with Glyburide.
Glipizide The risk or severity of hypoglycemia can be increased when Clofibrate is combined with Glipizide.
Gliclazide The risk or severity of hypoglycemia can be increased when Clofibrate is combined with Gliclazide.
Tolbutamide The risk or severity of hypoglycemia can be increased when Clofibrate is combined with Tolbutamide.
Gliquidone The risk or severity of hypoglycemia can be increased when Clofibrate is combined with Gliquidone.
Glisoxepide The risk or severity of hypoglycemia can be increased when Clofibrate is combined with Glisoxepide.
Glibornuride The risk or severity of hypoglycemia can be increased when Clofibrate is combined with Glibornuride.
Carbutamide The risk or severity of hypoglycemia can be increased when Clofibrate is combined with Carbutamide.
Metahexamide The risk or severity of hypoglycemia can be increased when Clofibrate is combined with Metahexamide.
Colestipol Colestipol can cause a decrease in the absorption of Clofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sevelamer Sevelamer can cause a decrease in the absorption of Clofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colesevelam Colesevelam can cause a decrease in the absorption of Clofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cholestyramine Cholestyramine can cause a decrease in the absorption of Clofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Erlotinib The serum concentration of Erlotinib can be decreased when it is combined with Clofibrate.
Dicoumarol The risk or severity of bleeding can be increased when Clofibrate is combined with Dicoumarol.
Phenindione The risk or severity of bleeding can be increased when Clofibrate is combined with Phenindione.
Coumarin The risk or severity of bleeding can be increased when Clofibrate is combined with Coumarin.
Tioclomarol The risk or severity of bleeding can be increased when Clofibrate is combined with Tioclomarol.
Ethyl biscoumacetate The risk or severity of bleeding can be increased when Clofibrate is combined with Ethyl biscoumacetate.
Diphenadione The risk or severity of bleeding can be increased when Clofibrate is combined with Diphenadione.
4-hydroxycoumarin The risk or severity of bleeding can be increased when Clofibrate is combined with 4-hydroxycoumarin.
Fluindione The risk or severity of bleeding can be increased when Clofibrate is combined with Fluindione.
Clorindione The risk or severity of bleeding can be increased when Clofibrate is combined with Clorindione.
Tacrolimus Tacrolimus may increase the nephrotoxic activities of Clofibrate.
Pravastatin The risk or severity of myopathy and rhabdomyolysis can be increased when Clofibrate is combined with Pravastatin.
Cerivastatin The risk or severity of myopathy and rhabdomyolysis can be increased when Clofibrate is combined with Cerivastatin.
Atorvastatin The risk or severity of myopathy and rhabdomyolysis can be increased when Clofibrate is combined with Atorvastatin.
Fluvastatin The risk or severity of myopathy and rhabdomyolysis can be increased when Clofibrate is combined with Fluvastatin.
Rosuvastatin The risk or severity of myopathy and rhabdomyolysis can be increased when Clofibrate is combined with Rosuvastatin.
Mevastatin The risk or severity of myopathy and rhabdomyolysis can be increased when Clofibrate is combined with Mevastatin.
Pitavastatin The risk or severity of myopathy and rhabdomyolysis can be increased when Clofibrate is combined with Pitavastatin.
Lovastatin The risk or severity of myopathy and rhabdomyolysis can be increased when Clofibrate is combined with Lovastatin.
Simvastatin The risk or severity of myopathy and rhabdomyolysis can be increased when Clofibrate is combined with Simvastatin.
Pitolisant The serum concentration of Clofibrate can be decreased when it is combined with Pitolisant.
Segesterone acetate The metabolism of Segesterone acetate can be increased when combined with Clofibrate.
Metreleptin The metabolism of Clofibrate can be increased when combined with Metreleptin.
Diethylstilbestrol The metabolism of Diethylstilbestrol can be increased when combined with Clofibrate.
Etonogestrel The metabolism of Etonogestrel can be increased when combined with Clofibrate.
Desogestrel The metabolism of Desogestrel can be increased when combined with Clofibrate.
Megestrol acetate The metabolism of Megestrol acetate can be increased when combined with Clofibrate.
Levonorgestrel The metabolism of Levonorgestrel can be increased when combined with Clofibrate.
Progesterone The metabolism of Progesterone can be increased when combined with Clofibrate.
Medroxyprogesterone acetate The metabolism of Medroxyprogesterone acetate can be increased when combined with Clofibrate.
Norethisterone The metabolism of Norethisterone can be increased when combined with Clofibrate.
Estradiol The metabolism of Estradiol can be increased when combined with Clofibrate.
Ethynodiol diacetate The metabolism of Ethynodiol diacetate can be increased when combined with Clofibrate.
Mifepristone The metabolism of Mifepristone can be increased when combined with Clofibrate.
Norgestimate The metabolism of Norgestimate can be increased when combined with Clofibrate.
Mestranol The metabolism of Mestranol can be increased when combined with Clofibrate.
Drospirenone The metabolism of Drospirenone can be increased when combined with Clofibrate.
Estrone sulfate The metabolism of Estrone sulfate can be increased when combined with Clofibrate.
Octylphenoxy polyethoxyethanol The metabolism of Octylphenoxy polyethoxyethanol can be increased when combined with Clofibrate.
Cyproterone acetate The metabolism of Cyproterone acetate can be increased when combined with Clofibrate.
Trestolone The metabolism of Trestolone can be increased when combined with Clofibrate.
Norelgestromin The metabolism of Norelgestromin can be increased when combined with Clofibrate.
Gestodene The metabolism of Gestodene can be increased when combined with Clofibrate.
Hydroxyprogesterone caproate The metabolism of Hydroxyprogesterone caproate can be increased when combined with Clofibrate.
Dienogest The metabolism of Dienogest can be increased when combined with Clofibrate.
Norethynodrel The metabolism of Norethynodrel can be increased when combined with Clofibrate.
Norgestrel The metabolism of Norgestrel can be increased when combined with Clofibrate.
Cloprostenol The metabolism of Cloprostenol can be increased when combined with Clofibrate.

Target Protein

Peroxisome proliferator-activated receptor alpha PPARA
Lipoprotein lipase LPL

Referensi & Sumber

Synthesis reference: Jones, W.G.M.,Thorp, J.M. and Waring, W.S.; U.S. Patent 3,262,850; July 26, 1966; assigned to Imperial Chemical Industries Limited, England.

Contoh Produk & Brand

Produk: 4 • International brands: 9
Produk
  • Atromid S Cap 500mg
    Capsule • 500 mg / cap • Oral • Canada • Approved
  • Atromid-S 1gm
    Capsule • 1 g / cap • Oral • Canada • Approved
  • Atromid-S Cap 500mg
    Capsule • 500 mg / cap • Oral • Canada • Approved
  • Novo-fibrate Cap 500mg
    Capsule • 500 mg / cap • Oral • Canada • Generic • Approved
International Brands
  • Alufibrate — The Central
  • Atromid-S
  • Binograc — Kotobuki Seiyaku
  • Clobrate — Johnson
  • ELPI
  • Hisunsero — Newai Chem
  • Koliva — Golden Horse
  • Lipofacton
  • Myanlin — Sinton

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul